Additional reduction in blood pressure after cholesterol-lowering treatment by statins (Lovastatin or Pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (Enalapril or Lisinopril)

American Journal of Cardiology

Volumn 83, Issue 10, 1999, Pages 1497-1499

  Spósito, Andrei C ^a   Mansur, Antonio P ^a   Coelho, Otavio R ^a   Nicolau, Jose C ^a   Ramires, Jose A F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LISINOPRIL; MEVINOLIN; PRAVASTATIN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; DRUG INTERACTIONS; ENALAPRIL; FEMALE; HEART RATE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LISINOPRIL; LOVASTATIN; MALE; MIDDLE AGED; PRAVASTATIN;

EID: 2542507788     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00132-0     Document Type: Article

References (21)

1. Lewis T.V., Cooper B.A., Dart A.M., Chin-Dusting J.P. Responses to endothelium-dependent agonists in subcutaneous arteries excised from hypercholesterolaemic men. Br J Pharmacol. 124:1998;222-228.
2. Stroes E., de Bruin T., de Valk H., Erkelens W., Banga J.D., van Rijn H., Koomans H., Rabelink T. NO activity in familial combined hyperlipidemia potential role of cholesterol remnants . Cardiovasc Res. 36:1997;445-452.
3. Stroes E.S., Koomans H.A., de Bruin T.W., Rabelink T.J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 346:1995;467-471.
4. Vidal F., Colome C., Martinez-Gonzalez J., Badimon L. Atherogenic concentrations of native low-density lipoproteins down-regulate nitric-oxide-synthase mRNA and protein levels in endothelial cells. Eur J Biochem. 252:1998;378-384.
5. Kotchen T.A., Talwalkar R.T. Increased enzymatic activity of renin and hyperlipidemia. Am J Physiol. 240:1981;E60-E64.
6. Alderman M.H., Ooi W.L., Cohen H., Madhavan S., Sealey J.E., Laragh J.H. Plasma renin activity a risk factor for myocardial infarction in hypertensive patients . Am J Hypertens. 10:1997;1-8.
7. Allikmets K., Parik T., Teesalu R. Association between plasma renin activity and metabolic cardiovascular risk factors in essential hypertension. J Intern Med. 239:1996;49-55.
8. Gleason M.M., Medow M.S., Tulenko T.N. Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells. Circ Res. 69:1991;216-227.
9. Sen L., Bialecki R.A., Smith E., Smith T.W., Colucci W.S. Cholesterol increases the L-type voltage-sensitive calcium channel current in arterial smooth muscle cells. Circ Res. 71:1992;1008-1014.
10. Ohya Y., Abe I., Fujii K., Takata Y., Fujishima M. Voltage-dependent Ca2+ channels in resistance arteries from spontaneously hypertensive rats. Circ Res. 73:1993;1090-1099.
11. Rubattu S., Volpe M., Enea I., Russo R., Romano M., Trimarco B. Influence of hypercholesterolemia on adrenal steroid metabolism and electrolyte balance in spontaneously hypertensive rats. Endocrinology. 133:1993;2015-2021.
12. Mangiafico R.A., Malatino L.S., Santonocito M., Spada R.S., Polizzi G., Tamburino G. Raised plasma endothelin-1 concentrations in patients with primary hypercholesterolemia without evidence of atherosclerosis. Int Angiol. 15:1996;240-244.
13. Lerman A., Webster M.W., Chesebro J.H., Edwards W.D., Wei C.M., Fuster V., Burnett J.C. Jr. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 88:1993;2923-2928.
14. Carleton R.A., Dwyer J., Finberg L. Report of the expert panel on population strategies for blood cholesterol reduction. Circulation. 83:1991;2154-2232.
15. Arch Intern Med. 153:1993;154-183.
16. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
17. Laufs U., La Fata V, Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
18. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., Sanchez-Pascuala R., Hernandez G., Diaz C., Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 101:1998;2711-2719.
19. Ng L.L., Davies J.E., Wojcikiewicz R.J. 3-Hydroxy-3-methyl glutaryl coenzyme A reductase inhibition modulates vasopressin-stimulated Ca2+ responses in rat A10 vascular smooth muscle cells. Circ Res. 74:1994;173-181.
20. Patrignani P, Daffonchio L, Hernandez A, De Caterina R, Pelosi G, Patrono C. Release of contracting autacoids by aortae of normal and atherosclerotic rabbits. J Cardiovasc Pharmacol 1992;20(suppl)12:S208-S210.
21. Haak T, Haak E, Kusterer K, Weber A, Kohleisen M, Usadel K. Fenofibrate improves microcirculation in patients with hyperlipidemia. Eur J Med Res 1998;3:50-54.